Genome-Based Drug Target Identification in Human Pathogen Streptococcus gallolyticus

Area of Science:

• Microbiology
• Computational Biology
• Drug Discovery

Background:

• Streptococcus gallolysticus (Sg) is an opportunistic pathogen causing infective endocarditis.
• Increasing antibiotic resistance in Sg necessitates novel therapeutic strategies and drug targets.

Purpose of the Study:

• To identify potential therapeutic targets and drug candidates against Sg using an in silico approach.
• To leverage genomic and proteomic data for novel drug and vaccine target discovery.

Main Methods:

• Pan-genomic analysis to identify 1,138 core proteins in Sg.
• Subtractive proteomic analysis to select 18 essential, non-human homologous proteins.
• Molecular docking of selected proteins against drug-like compounds from the ZINC database.

Main Results:

• Identified 12 cytoplasmic proteins as potential drug targets.
• Screened compounds against these targets, identifying those with lower binding energy.
• Discovered novel drug and vaccine targets for Sg, some previously validated in other species.

Conclusions:

• The in silico methodology provides a significant contribution to identifying drug/vaccine targets for Sg.
• The identified targets and compounds offer a promising avenue for combating Sg-induced infective endocarditis.
• This study lays the groundwork for experimental validation of novel therapeutic strategies against Sg.